Cooperative Agreement R43CA224824

This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $399,491 to Northridge Tri-Modality Imaging Inc. to upgrade their gantry-based imaging system to incorporate bioluminescence tomography (BLT) capabilities. The upgraded system will enable 3D whole-body fluorescent, bioluminescent, and anatomical X-ray imaging of small animal cancer models, providing a comprehensive multimodal imaging...

Federal Grant Award Summary Metastx LLC received a $399,954 Project Grant from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) awarded July 1, 2025, with completion targeted for June 30, 2026. The company will develop a novel predictive model for metastatic prostate cancer by integrating epithelial-mesenchymal transition (EMT) signature markers with machine learning-based analysis and advanced imaging technologies. The project...

Summary The National Cancer Institute awarded a $358,605 Project Grant to The University of Texas MD Anderson Cancer Center under the Cancer Detection and Diagnosis Research program (CFDA 93.394) on September 8, 2025, for a pilot study extending through August 31, 2027. The project will develop and validate 4-[18F]fluoro-1-naphthol (4FN) positron emission tomography/computed tomography (PET/CT) imaging as a novel diagnostic and prognostic biomarker for chronic graft-versus-host disease (GVHD) in...

The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded Loyola University of Chicago a $461,844 project grant titled "Hyperpolarized 13C Metabolic Imaging of Tumorigenesis in the Liver". The objective is to use novel hyperpolarized 13C probes to image glycolysis, a critical pathway in hepatocellular carcinoma (HCC) development, and establish in vivo imaging biomarkers to assess altered liver metabolism during HCC progression. The project aims to synthesize a...

This Project Grant award of $466,500.00 from the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research program (CFDA 93.121), aims to develop near-infrared chemiluminescent and fluorescent (NIR CFL) chitosan-based nanoparticles (CNPs) to improve the detection of micrometastatic cancer and guide image-guided surgery. The nanoparticles can be activated by body heat and stored at low temperatures for convenience and safety. The research...

Visikol Inc. received a $4,103,265 Project Grant award from the National Cancer Institute, a division of the Department of Health and Human Services, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award will support the development of a 3D imaging diagnostic tool to improve characterization of metastatic melanoma in sentinel lymph node biopsies. Visikol will conduct a retrospective clinical study using archived negative sentinel lymph node biopsy tissue blocks to...

This Project Grant award from the National Institutes of Health (NIH) Research Infrastructure Programs (CFDA 93.351) provides $270,428 to TEO Therapeutics Incorporated, a small disadvantaged business, to develop a biomimetic platform for more efficient pharmaceutical drug development in oncology. The key products and services to be delivered include: Refining and testing a proof-of-concept hardware product line for a Shell-Free Quail Xenograft Assay, optimizing throughput and assessing...

The University of Michigan has been awarded a $568,151 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to develop a real-time functional imaging platform for accurate diagnosis and prognosis of prostate cancer. The project aims to leverage photoacoustic imaging and biocompatible hydrogel nanoparticle probes to quantitatively assess prostate gland microarchitecture and tumor microenvironment as imaging biomarkers for improved prostate...

This federal Project Grant award of $399,829, awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports research to validate the use of positron emission tomography (PET) imaging to quantitatively measure the levels of the sphingosine-1-phosphate receptor 1 (S1PR1) in gastric tumors. The goal is to use this S1PR1-targeted PET imaging approach to predict and monitor the response of gastric tumors to antibody-drug conjugate...

This $384,863 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286) program supports research to develop a novel radiotracer imaging agent for detecting Gram-positive bacterial infections associated with implanted medical devices. The key products and services to be delivered include: In vitro testing of a bivalent radiotracer agent...